TrialSite News reported on Aug 22 that a South Texas trial site location reported growing confidence in a SARS-CoV-2 neutralizing antibody-based investigational product developed by Eli Lilly (Lilly) called LY-CoV555. Developed with the help of powerful discovery...
AbCellera
Category
Eli Lilly’s BLAZE-1 Selects Aventiv Research in Columbus as Ohioans Investigate Advanced Monoclonal Antibodies Targeting COVID-19
TrialSite recently profiled Columbus, Ohio-based Aventiv Research as the independent trial site organization was selected by Pfizer as a site to participate in the BNT162 COVID-19 vaccine trial program. Now, local media (WSYX/WTTE) reports that the Columbus-based site...
Lilly’s LY-CoV555 Shows Promise Targeting COVID-19 With Phase 2 Interim Analysis
Eli Lilly and Company (NYSE: LLY) announced that proof of concept data from an interim analysis of the BLAZE-1 clinical trial reveals a reduced rate of hospitalization for patients treated with LY-CoV555. An ongoing randomized, double-blind, placebo-controlled Phase 2...
NIAID Launching ACTIV-2 Adaptive Trial to Investigative Use of Lilly’s LY-COV555 & Other MABs
The National Institutes of Allergy and Infectious Diseases (NIAID), led by Dr. Anthony Fauci, continues to drive research, full throttle, during the COVID-19 pandemic. Now NIAID will sponsor a Phase 2 clinical trial evaluating the safety and efficacy of a potential...
Prominent New Orleans Physician Discusses Participation in Blaze-1 Study of World’s First Antibody Product Targeting COVID-19
Louisiana’s Ochsner Medical Center in Jefferson Parish is actively contributing its medical, scientific and research talents in the ongoing bid to combat the COVID-19 pandemic. Partnering with industry sponsors such as Eli Lilly, one the health provider’s prestigious...